Get informed when a big investor buys or sells
+ Follow-524.74%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
ReNeuron Group plc (RNUGF) currently reports a ROE of -524.74%. That is below the Healthcare sector average of 13.1%. Use the charts on this page to explore ReNeuron Group plc's ROE history and peer comparisons.
ReNeuron Group plc's ROE of -524.74% is lower than the Healthcare sector average of 13.1%. That is roughly 4104.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but ReNeuron Group plc's current -524.74% should be judged against Healthcare norms (sector average: 13.1%) and against RNUGF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -524.74%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for ReNeuron Group plc, and consider following RNUGF for alerts when major investors trade the stock.
ReNeuron Group plc is classified in the Healthcare sector. On ROE, it currently shows -524.74% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RNUGF with unrelated industries.